Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.73 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.73 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162036 | 1.00 | DPP4 (1.00) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL1040802 | 1.00 | DPP4 (1.00) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL2555136 | 1.00 | DPP4 (1.00) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL163502 | 1.00 | DPP4 (1.00) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL13882110 | 0.96 | DPP4 (0.92) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL14648444 | 0.96 | DPP4 (0.92) | DPP4DPP9DPP8PIK3CA | |
| SCHEMBL18175266 | 0.96 | DPP4 (0.92) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL2742696 | 0.96 | DPP4 (0.92) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL13287073 | 0.96 | DPP4 (0.92) | DPP4DPP9DPP8PIK3CAPREP | |
| SCHEMBL11998124 | 0.91 | DPP4 (0.83) | DPP4DPP9DPP8PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| CN-119698278-A | Small molecule modulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2025-03-25 | — | — | CN | claimed |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | claimed |
| WO-2024015889-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-18 | — | — | WO | claimed |
| US-20220117960-A1 | DIPEPTIDYLPEPTIDASE 4 INHIBITION ENHANCES LYMPHOCYTE TRAFFICKING, IMPROVING BOTH NATURALLY OCCURRING TUMOR IMMUNITY AND IMMUNOTHERAPY | INSTITUT PASTEUR (FR) | 2022-04-21 | — | — | US | claimed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | claimed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | claimed |
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | ABBVIE INC (US) | 2016-06-02 | — | — | US | claimed |
| US-9260411-B2 | Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile | ABBVIE INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | claimed |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | ABBVIE INC. | 2008-03-06 | — | — | US | claimed |
| EP-1560811-B9 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2008-03-05 | — | — | EP | claimed |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | MADAR DAVID J | 2007-11-15 | — | — | US | claimed |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | MADAR DAVID J | 2007-10-11 | — | — | US | claimed |
| US-7262207-B2 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES (US) | 2007-08-28 | — | — | US | claimed |
| EP-1560811-B1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | ABBOTT LAB (US) | 2007-08-01 | — | — | EP | claimed |
| US-7238724-B2 | Antidiabetic agents; hyperlipemic agents; obestity; immunomoderator; atherosclerosis | ABBOTT LABORATORIES (US) | 2007-07-03 | — | — | US | claimed |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2005-09-29 | — | — | US | claimed |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBVIE INC. | 2004-12-23 | — | — | US | claimed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152600-A1 | SYNTHESIS OF (2S,5R)-5-ETHYNYL-1-PYRROLIDINE-2-CARBONITRILE | PNN, PARN, AZI2 | DPP4 1253/4885DPP9 2653/4885DPP8 2673/4885 |
| US-20070265302-A1 | PHARMACEUTICAL COMPOSITIONS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
| US-20080058528-A1 | useful in the treatment of disorders mediated by DPP-IV such as, but not limited to, diabetes, type II diabetes, hyperglycemia, Syndrome X, hyperinsulinemia and obesity | DPP4, DPP7, DPP3 | DPP4 1/4885DPP9 5/4885DPP8 4/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
| US-20050215784-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
| US-20070238753-A1 | Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
| US-20040259843-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | DPP4 1/4885DPP9 4/4885DPP8 5/4885 |
| US-20240115577-A1 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | DPP4, DPP7, ING2 | DPP4 1/4885DPP9 15/4885DPP8 8/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | DPP4 5/4885DPP9 3/4885DPP8 12/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | DPP4 6/4885DPP9 10/4885DPP8 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.